2012 BIO International Convention
June 18-21, 2012 Boston, Massachusetts
Session Track Descriptions
1. Achieving Regulatory Approval and Compliance: Regulatory and legal developments at the Food and Drug Administration (FDA) and across the globe that will affect biotech companies’ ability to research and develop the healthcare products, successfully bring these products to market, and maintain approval and compliance. Session length: 75 to 90 minutes
2. Biofuels & Biobased Chemicals: Breakthrough industrial biotechnologies for biofuels, renewable chemicals, and biobased products making manufacturing processes cleaner and more efficient, creating new materials, food ingredients and other products, unlocking cleaner and greener sources of energy, and reducing industrial waste. Session length: 75 to 90 minutes
3. Biotech Patenting and Tech Transfer: Latest trends in intellectual property protection for biotech innovations, and pragmatic approaches to challenges and opportunities in global biotech licensing, tech transfer, and collaborations. Session length: 75 to 90 minutes
4. Business Development: Analysis of the latest biotech partnering and alliance deal trends. Session length: 75 to 90 minutes
5. Drug Discovery & Development: Discovery research, preclinical safety assessment, clinical trials, and more. Session length: 75 to 90 minutes
6. Finance: Analysis of the latest biotech financing, investment and deal trends. Session length: 75 to 90 minutes
7. Food & Agriculture: Moving Beyond the Debate: Effectively Addressing Global Regulatory and Acceptance Issues to Realize Agricultural Biotechnology’s Full Potential. Topics could include: emerging markets and grain trade issues; U.S. regulations and impediments to international competitiveness; new genetic modification technologies: science, applications and issues; Ag biotech’s role in strengthening rural economies, job creation, and trade; working with like-minded countries to establish trade and regulatory cooperation; coexistence; agricultural research/extension programs/land grant universities; GE animal regulatory issues – domestic and international; challenges and opportunities of emerging biotechnology companies; stewardship – the movement of a biotechnology product from the lab to the end of the supply chain; agricultural energy – examining federal programs, partnerships and policies, and the future of biotechnology to U.S. and global energy security; the Coordinated Framework after 25 years; and effectively addressing consumer attitudes and acceptance. Session length: 75 to 90 minutes
8. Global Innovations & Markets: In-depth analysis of biotechnology market opportunities and innovation systems, especially in emerging economies. Session length: 75 to 90 minutes
9. Health Policy & Reimbursement: Emerging health policy issues and key developments impacting the market and reimbursement landscape for innovative biopharmaceutical therapies. BIO is seeking submissions related to policy developments related to accountable care organizations; Patient-Centered Outcomes Research Institute (PCORI) and comparative effectiveness research; health insurance exchanges, the essential benefits package, and the impact on drug formularies; the shifting role of Medicaid and impact on biopharmaceuticals; investor perspectives on reimbursement; and federal budget cuts, the IPAB and the impact on biopharmaceuticals. Session length: 75 to 90 minutes
10. Innovations in Vaccines: Exciting updates on the newest developments in vaccines for prevention and treatment from infectious diseases to cancer. Topics could include: the impact of healthcare reform on vaccines business opportunity; international opportunities for vaccine group; therapeutic vaccines; influenza vaccines; and emerging infections –dengue, hospital-acquired infections, etc. Session length: 75 to 90 minutes
11. International Case Studies: 45-minute sessions where countries and regions around the world will present specific initiatives to generate promising new discoveries, create jobs, and spur economic growth and development. Challenges as well as successful examples on what it takes to create local, national, and/or regional value in this highly innovative technology sector will be discussed. Individuals with Exhibit Booth Personnel registrations are allowed to attend this track. (Note: Priority as session organizer is given to International Delegation and Pavilion Organizers. Submissions from clusters and individual companies will not be considered for this track. BIO will be accepting submissions online from October 3 -October 28, 2011).Session length: 45 minutes
12. Manufacturing of Biologics & Drugs: Recent developments in biologics and drug manufacturing, including quality-by-design, process analytical technology, compliance activities, and supply chain management. Session length: 75 to 90 minutes
13. Personalized Medicine & Diagnostics: From R&D, through regulatory oversight, to reimbursement and patient access: the development of novel diagnostic technologies and the related therapeutics that they target in the evolving healthcare system. Session length: 75 to 90 minutes
Contact Us
Program Inquiries
program@bio.org
Exhibiting or Advertising
exhibit@bio.org
General Questions
reg2012@bio.org
Housing
BIO@tphousing.com
